Orchid Pharma Ltd (ORCHPHARMA) Q4FY26 Management Mirror - Mar-2026 Qtr
Base Business & Margins
Management upgraded FY27 base business EBITDA margin guidance to approximately 12% in the Mar'26 Qtr, up from the 10% directional target provided in the Dec'25 Qtr, driven by margin recovery and stabilization past the pricing cycle bottom. Revenue growth is targeted at 10% to 15% YoY for FY27. Earlier in the Sep'25 Qtr, the outlook was muted with no near-term revival signs, but by the Dec'25 Qtr, expectations improved for non-regulated market margins due to raw material price recovery. [Status: Upgraded]
5 more themes on the ELITE plan.